These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 8951366)
1. Will molecular biology provide oncologists with information useful for risk assessment, prognosis, or therapeutic decisions in cancer patients? Head JF Cancer Invest; 1996; 14(6):635-6. PubMed ID: 8951366 [No Abstract] [Full Text] [Related]
2. Elevated expression of ferritin H-chain mRNA in metastatic ovarian tumor. Tripathi PK; Chatterjee SK Cancer Invest; 1996; 14(6):518-26. PubMed ID: 8951356 [TBL] [Abstract][Full Text] [Related]
3. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Yang DC; Wang F; Elliott RL; Head JF Anticancer Res; 2001; 21(1B):541-9. PubMed ID: 11299801 [TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. D'Antonio A; Losito S; Pignata S; Grassi M; Perrone F; De Luca A; Tambaro R; Bianco C; Gullick WJ; Johnson GR; Iaffaioli VR; Salomon DS; Normanno N Int J Oncol; 2002 Nov; 21(5):941-8. PubMed ID: 12370739 [TBL] [Abstract][Full Text] [Related]
6. The human kallikrein gene family: new biomarkers for ovarian cancer. Yousef GM; Diamandis EP Cancer Treat Res; 2009; 149():165-87. PubMed ID: 19763436 [No Abstract] [Full Text] [Related]
7. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones]. Yan XD; Pan LY Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965 [TBL] [Abstract][Full Text] [Related]
8. Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer. Baron AT; Lafky JM; Boardman CH; Cora EM; Buenafe MC; Liu D; Rademaker A; Fishman DA; Podratz KC; Reiter JL; Maihle NJ Cancer Treat Res; 2009; 149():189-202. PubMed ID: 19763437 [No Abstract] [Full Text] [Related]
9. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Vasaikar SV; Straub P; Wang J; Zhang B Nucleic Acids Res; 2018 Jan; 46(D1):D956-D963. PubMed ID: 29136207 [TBL] [Abstract][Full Text] [Related]
10. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. Mills GB; Bast RC; Srivastava S J Natl Cancer Inst; 2001 Oct; 93(19):1437-9. PubMed ID: 11584052 [No Abstract] [Full Text] [Related]
12. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Varambally S; Yu J; Laxman B; Rhodes DR; Mehra R; Tomlins SA; Shah RB; Chandran U; Monzon FA; Becich MJ; Wei JT; Pienta KJ; Ghosh D; Rubin MA; Chinnaiyan AM Cancer Cell; 2005 Nov; 8(5):393-406. PubMed ID: 16286247 [TBL] [Abstract][Full Text] [Related]
13. Carcinofetal human isoferritins. Drysdale JW; Alpert E Ann N Y Acad Sci; 1975 Aug; 259():427-34. PubMed ID: 173233 [No Abstract] [Full Text] [Related]
14. Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation. Hill BT; Whelan RD; Hurst HC; McClean S Cancer; 1994 Jun; 73(12):2990-9. PubMed ID: 7911070 [TBL] [Abstract][Full Text] [Related]
15. Location of BRCA1 in human breast and ovarian cancer cells. Scully R; Ganesan S; Brown M; De Caprio JA; Cannistra SA; Feunteun J; Schnitt S; Livingston DM Science; 1996 Apr; 272(5258):123-6. PubMed ID: 8600523 [No Abstract] [Full Text] [Related]
16. Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Mattern J; Stammler G; Koomagi R; Wallwiener D; Kaufmann M; Volm M Anticancer Res; 1997; 17(1B):621-4. PubMed ID: 9066589 [TBL] [Abstract][Full Text] [Related]
17. Breast cancer genes: therapeutic strategies. Holt JT Ann N Y Acad Sci; 1997 Dec; 833():34-41. PubMed ID: 9616738 [TBL] [Abstract][Full Text] [Related]
18. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Wilson KE; Langdon SP; Lessells AM; Miller WR Br J Cancer; 1996 Oct; 74(7):999-1004. PubMed ID: 8855965 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic and biological determinants in undifferentiated and poorly differentiated ovarian carcinomas. Canzonieri V; Viel A; Visentin MC; Perin T; Sopracordevole F; Dall'Agnese L; Scara-Belli C; Boiocchi M; Carbone A Pathologica; 1995 Oct; 87(5):492-7. PubMed ID: 8868173 [TBL] [Abstract][Full Text] [Related]
20. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. Gortzak-Uzan L; Ignatchenko A; Evangelou AI; Agochiya M; Brown KA; St Onge P; Kireeva I; Schmitt-Ulms G; Brown TJ; Murphy J; Rosen B; Shaw P; Jurisica I; Kislinger T J Proteome Res; 2008 Jan; 7(1):339-51. PubMed ID: 18076136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]